Immunocore: Initial Phase 1 data for first soluble TCR therapy for people living with HIV

 Data from the single ascending dose part of thePhase 1 trial showsIMC-M113V is well tolerated

Expected markers of T cell activation observed in half of participants at 15-mcg dose;plasma viral load remained suppressed throughout dosing and follow-up

The multiple ascending dose part of the trial is enrolling participants to identify safety and anti-viral activity

https://www.biospace.com/article/releases/immunocore-announces-initial-phase-1-safety-and-pharmacodynamic-activity-data-with-first-soluble-tcr-therapy-for-people-living-with-hiv/